Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma
Forberg, Aidan L., Unrau, Jordan, Weber, Kennedee S., Rutz, Alison C., Lund, Shelby, Guidinger, Jinda, Pelzel, Andrew, Hauge, Jackson, Hemmen, Ainslee J., Hartert, Keenan T.
Published in Annals of hematology (2024)
Published in Annals of hematology (2024)
Get full text
Journal Article
EFS24 Failure, BRD4 Expression, and TP53 Are Linked to Reduced CDKN1A Expression in DLBCL and May be Targeted By Single-Agent Protac ARV-825 or in Synergistic Combination with the CDK4/6 Inhibitor Abemaciclib
Rutz, Alison, Weber, Kennedee, Lund, Shelby, Guidinger, Jinda, Forberg, Aidan, Hartert, Keenan T.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
The DLBCL Axis of Low TNFRSF10B Expression, TP53 Loss, and a Cold Immune Microenvironment May be Addressed By the Synergistic Combination of Eprenetapopt and Idasnutlin
Rutz, Alison, Lund, Shelby, Guidinger, Jinda, Weber, Kennedee, Forberg, Aidan, Hartert, Keenan T.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Cooperative Networks between MYC and XPO1 Associated with Decreased T-Cell Presence and a Depleted Tumor Microenvironment May be Addressed By the Synergistic Combination of AZD4573 and Selinexor
Weber, Kennedee, Forberg, Aidan, Unrau, Jordan, Rutz, Alison, Lund, Shelby, Hauge, Jackson, Hemmen, Ainslee, Hartert, Keenan T
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article